Treating Highly Sensitized Patients on the Kidney Transplant Waiting List by Depleting Their B-cells Using Chimeric Antigen Receptor T Cells (CAR-T)

Overview

About this study

The purpose of this study is to decrease the waiting time on the transplant list for patients who have high level of anti-HLA antibodies with ESRD and improve the patients and allograft survival after transplant.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

We will treat the blood samples, in vitro, that are obtained from 10 adult patients listed for kidney, heart or lung transplant at Mayo clinic transplant center and:

Adult patients 18 years of age and above
Willing to sign informed consent.
Highly sensitized with cPRA of 98% and greater
Willing to provide clinical data and blood samples.

Exclusion Criteria:

We will exclude:

Any patients who received a desensitization therapy including any monoclonal antibodies, plasmapheresis, and/or splenectomy
Inability to understand and sign informed consent.

Eligibility last updated 10/14/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Jacksonville, Fla. Mayo Clinic principal investigator Tambi Jarmi, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Tambi Jarmi, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials